Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Significance: Human microglia, the resident immune cells of the brain, express only the neurotensin (NT) receptor-3/sortilin. NT significantly increases microglia synthesis and release of proinflammatory cytokine IL-1β and chemokine (C-X-C motif) ligand 8 (CXCL8), chemokine (C-C motif) ligand 2 (CCL2), and CCL5 via NTR3/sortilin. A soluble form of this receptor is secreted from stimulated microglia and is increased in the serum of children with autism spectrum disorders (ASD). These responses and the NT-stimulated increases in microglia numbers are mediated via mammalian target of rapamycin (mTOR) activation and are inhibitable by the natural flavonoids luteolin and methoxyluteolin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Middleton, E., Kandaswami, C., & Theoharides, T. C. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01472-8 · Cited by 4,882
Self-citationSynaptic Pruning by Microglia Is Necessary for Normal Brain Development
Paolicelli, R. C., Bolasco, G., Pagani, F., Maggi, L., Scianni, M., Panzanelli, P., Giustetto, M., Ferreira, T. A., Guiducci, E., Dumas, L., et al. (2011) · Science · doi:10.1126/science.1202529 · Cited by 4,244 · cited 1×
“Microglia, the highly plastic resident immune cells of the brain (6, 7), have been shown to be activated in the brains of patients with ASD (8–11).”
BackgroundGenomic responses in mouse models poorly mimic human inflammatory diseases
Seok, J., Warren, H. S., Cuenca, A. G., Mindrinos, M. N., Baker, H. V., Xu, W., Richards, D. R., McDonald-Smith, G. P., Gao, H., Hennessy, L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222878110 · Cited by 3,005
Neuroglial activation and neuroinflammation in the brain of patients with autism
Vargas, D. L., Nascimbene, C., Krishnan, C., Zimmerman, A. W., & Pardo, C. A. (2005) · Annals of Neurology · doi:10.1002/ana.20315 · Cited by 2,149 · cited 18×
“Stimulation by NT of microglia in which NTR3/sortilin levels were down-regulated significantly decreases (P 0.001) IL-1β, CXCL8, CCL2, and CCL5 release, compared with control cells (Fig.”
BackgroundInfluentialMicroglia-specific localisation of a novel calcium binding protein, Iba1
Ito, D., Imai, Y., Ohsawa, K., Nakajima, K., Fukuuchi, Y., & Kohsaka, S. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(98)00040-0 · Cited by 1,476 · cited 1×
“The colocalization of NTR3/sortilin with Iba-1, which interacts with actin and is often used to detect microglia (60), allowed us to speculate that Iba-1 may participate in movement of NTR3/sortilin to the cell surface.”
BackgroundRapamycin: one drug, many effects
Li, J., Kim, S. G., & Blenis, J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.001 · Cited by 1,287 · cited 1×
“Methoxyluteolin is a more potent inhibitor than luteolin or rapamycin (92) and other mTOR inhibitors (93), indicating that it could be developed into an effective treatment for ASD.”
BackgroundThe maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring
Choi, G. B., Yim, Y. S., Wong, H., Kim, S., Kim, H., Kim, S. V., Hoeffer, C. A., Littman, D. R., & Huh, J. R. (2016) · Science · doi:10.1126/science.aad0314 · Cited by 1,214 · cited 1×
“Increased levels of these mediators have been reported in the brains (8, 19) and blood (57, 58) of patients with ASD, as well as in mice with autistic-like behavior (59).”
BackgroundInterleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor
Hannum, C. H., Wilcox, C. J., Arend, W. P., Joslin, F. G., Dripps, D. J., Heimdal, P. L., Armes, L. G., Sommer, A., Eisenberg, S. P., & Thompson, R. C. (1990) · Nature · doi:10.1038/343336a0 · Cited by 1,122 · cited 15×
“Stimulation by NT of microglia in which NTR3/sortilin levels were down-regulated significantly decreases (P 0.001) IL-1β, CXCL8, CCL2, and CCL5 release, compared with control cells (Fig.”
BackgroundInfluentialPten Regulates Neuronal Arborization and Social Interaction in Mice
Kwon, C.-H., Luikart, B. W., Powell, C. M., Zhou, J., Matheny, S. A., Zhang, W., Li, Y., Baker, S. J., & Parada, L. F. (2006) · Neuron · doi:10.1016/j.neuron.2006.03.023 · Cited by 970
Ashwood, P., Krakowiak, P., Hertz-Picciotto, I., Hansen, R., Pessah, I., & Van de Water, J. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.08.003 · Cited by 940 · cited 18×
“Stimulation by NT of microglia in which NTR3/sortilin levels were down-regulated significantly decreases (P 0.001) IL-1β, CXCL8, CCL2, and CCL5 release, compared with control cells (Fig.”
BackgroundInfluentialThe TSC-mTOR Signaling Pathway Regulates the Innate Inflammatory Response
Weichhart, T., Costantino, G., Poglitsch, M., Rosner, M., Zeyda, M., Stuhlmeier, K. M., Kolbe, T., Stulnig, T. M., Hörl, W. H., Hengstschläger, M., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.012 · Cited by 801 · cited 1×
“This effect may be mediated via the activation of nuclear factor-kappa B (NF-ĸB) (67) and the signal transducer and activator of transcription (STAT) pathways (68), critical for transcription of proinflammatory cytokines and chemokines (69).”
BackgroundElevated immune response in the brain of autistic patients
Li, X., Chauhan, A., Sheikh, A. M., Patil, S., Chauhan, V., Li, X.-M., Ji, L., Brown, T., & Malik, M. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.12.002 · Cited by 786
Butler, M. G., Dasouki, M. J., Zhou, X.-P., Talebizadeh, Z., Brown, M., Takahashi, T. N., Miles, J. H., Wang, C. H., Stratton, R., Pilarski, R., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.024646 · Cited by 778 · cited 1×
“These findings provide evidence why some patients with ASD who have gene mutations in one negative regulatory protein of mTOR, the phosphatase and tensin homolog (63, 64), develop inflammation of the brain that is linked to ASD pathogenesis (65, 66).”
BackgroundMorgan, J. T., Chana, G., Pardo, C. A., Achim, C., Semendeferi, K., Buckwalter, J., Courchesne, E., & Everall, I. P. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.024 · Cited by 749
Microglial Activation in Young Adults With Autism Spectrum Disorder
Suzuki, K., Sugihara, G., Ouchi, Y., Nakamura, K., Futatsubashi, M., Takebayashi, K., Yoshihara, Y., Omata, K., Matsumoto, K., Tsuchiya, K. J., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.272 · Cited by 523
Mast Cells, Mastocytosis, and Related Disorders
Theoharides, T. C., Valent, P., & Akin, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1409760 · Cited by 518
Self-citationImmune mediators in the brain and peripheral tissues in autism spectrum disorder
Estes, M. L., & McAllister, A. K. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3978 · Cited by 514
Gupta, S., Ellis, S. E., Ashar, F. N., Moes, A., Bader, J. S., Zhan, J., West, A. B., & Arking, D. E. (2014) · Nature Communications · doi:10.1038/ncomms6748 · Cited by 504
Wander, S. A., Hennessy, B. T., & Slingerland, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44145 · Cited by 427 · cited 1×
“Methoxyluteolin is a more potent inhibitor than luteolin or rapamycin (92) and other mTOR inhibitors (93), indicating that it could be developed into an effective treatment for ASD.”
BackgroundmTOR complexes in neurodevelopmental and neuropsychiatric disorders
Costa-Mattioli, M., & Monteggia, L. M. (2013) · Nature Neuroscience · doi:10.1038/nn.3546 · Cited by 367 · cited 1×
“These findings provide evidence why some patients with ASD who have gene mutations in one negative regulatory protein of mTOR, the phosphatase and tensin homolog (63, 64), develop inflammation of the brain that is linked to ASD pathogenesis (65, 66).”
BackgroundGaray, P. A., Hsiao, E. Y., Patterson, P. H., & McAllister, A. K. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.07.008 · Cited by 366 · cited 1×
“In vivo, luteolin reversed autism-like behavior in the maternal immune activation mouse model (50, 90, 91).”
BackgroundModeling an autism risk factor in mice leads to permanent immune dysregulation
Hsiao, E. Y., McBride, S. W., Chow, J., Mazmanian, S. K., & Patterson, P. H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202556109 · Cited by 340 · cited 1×
“In vivo, luteolin reversed autism-like behavior in the maternal immune activation mouse model (50, 90, 91).”
BackgroundCerebrospinal Fluid and Serum Markers of Inflammation in Autism
Zimmerman, A. W., Jyonouchi, H., Comi, A. M., Connors, S. L., Milstien, S., Varsou, A., & Heyes, M. P. (2005) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2005.03.014 · Cited by 300
Smith, A. M., & Dragunow, M. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2013.12.001 · Cited by 256 · cited 1×
“However, rodent microglia have major biochemical and pharmacological differences compared with primary human microglia (38).”
BackgroundEsposito, P., Chandler, N., Kandere, K., Basu, S., Jacobson, S., Connolly, R., Tutor, D., & Theoharides, T. C. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.038497 · Cited by 252
Self-citationMicroglia and mast cells: two tracks on the road to neuroinflammation
Skaper, S. D., Giusti, P., & Facci, L. (2012) · The FASEB Journal · doi:10.1096/fj.11-197194 · Cited by 235 · cited 3×
“The phosphoinositide 3-kinase (PI3K)/AKT/mTOR signaling pathway also regulates the activation of both microglia (44) and mast cells (45), which may cross-talk to exacerbate inflammation of the brain (15).”
BackgroundTsilioni, I., Taliou, A., Francis, K., & Theoharides, T. C. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.142 · Cited by 199 · cited 1×
“Increased levels of these mediators have been reported in the brains (8, 19) and blood (57, 58) of patients with ASD, as well as in mice with autistic-like behavior (59).”
BackgroundSelf-citationDysregulation of Mammalian Target of Rapamycin Signaling in Mouse Models of Autism
Huber, K. M., Klann, E., Costa-Mattioli, M., & Zukin, R. S. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2656-15.2015 · Cited by 167 · cited 1×
“These mutations in mice lead to a behavioral phenotype resembling autism (41), and targeting the mTOR pathway has been shown to reverse autism-like behavior (42, 43).”
BackgroundIntersection of mTOR and STAT signaling in immunity
Saleiro, D., & Platanias, L. C. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.10.006 · Cited by 142
Mast cells, brain inflammation and autism
Theoharides, T. C., Stewart, J. M., Panagiotidou, S., & Melamed, I. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.086 · Cited by 138
Self-citationDrug discovery for autism spectrum disorder: challenges and opportunities
Ghosh, A., Michalon, A., Lindemann, L., Fontoura, P., & Santarelli, L. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4102 · Cited by 108 · cited 1×
“Presently, there is no clinically effective drug to treat the pathophysiology of ASD (94).”
BackgroundKassai, H., Sugaya, Y., Noda, S., Nakao, K., Maeda, T., Kano, M., & Aiba, A. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.048 · Cited by 107 · cited 1×
“These findings provide evidence why some patients with ASD who have gene mutations in one negative regulatory protein of mTOR, the phosphatase and tensin homolog (63, 64), develop inflammation of the brain that is linked to ASD pathogenesis (65, 66).”
BackgroundFrom molecules to neural morphology: understanding neuroinflammation in autism spectrum condition
Young, A. M. H., Chakrabarti, B., Roberts, D., Lai, M.-C., Suckling, J., & Baron-Cohen, S. (2016) · Molecular Autism · doi:10.1186/s13229-016-0068-x · Cited by 76
Brain cytokines and neuropsychiatric disorders
Theoharides, T. C., Weinkauf, C., & Conti, P. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000148026.86483.4f · Cited by 56
Self-citation
Cited by
Butyrate and Dietary Soluble Fiber Improve Neuroinflammation Associated With Aging in Mice
Matt, S. M., Allen, J. M., Lawson, M. A., Mailing, L. J., Woods, J. A., & Johnson, R. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01832 · Cited by 330
The human microglial HMC3 cell line: where do we stand? A systematic literature review
Dello Russo, C., Cappoli, N., Coletta, I., Mezzogori, D., Paciello, F., Pozzoli, G., Navarra, P., & Battaglia, A. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1288-0 · Cited by 265
Microglia increase inflammatory responses in iPSC-derived human BrainSpheres
Abreu, C. M., Gama, L., Krasemann, S., Chesnut, M., Odwin-Dacosta, S., Hogberg, H. T., Hartung, T., & Pamies, D. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02766 · Cited by 123
Recent Research Trends in Neuroinflammatory and Neurodegenerative Disorders
Cohen, J., Mathew, A., Dourvetakis, K. D., Sanchez-Guerrero, E., Pangeni, R. P., Gurusamy, N., Aenlle, K. K., Ravindran, G., Twahir, A., Isler, D., et al. (2024) · Cells · doi:10.3390/cells13060511 · Cited by 103
“Instead, the flavonoids lute-olin (3,4,5,7-tetraxydroxyflavone) and tetramethoxyluteolin (3,4,5,7-tetramethoxyflavone) is a potent inhibitor of both human microglia [189] and human mast cells [190].”
BackgroundSelf-citationBawazeer, M. A., & Theoharides, T. C. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172760 · Cited by 70
Self-citation
Metadata
- Authors
- Patel, A. B., Tsilioni, I., Leeman, S. E., & Theoharides, T. C.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2016-09-23
- Volume
- 113
- Issue
- 45
- Pages
- E7049-E7058
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2522692264
- Cited by
- 120
- References
- 34
- FWCI
- 6.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.